Direct moxa can be defined as being when moxa is burnt right down to the skin. It was used a lot in China, often done with many cones causing deliberate blistering. There is also plenty of evidence dating back over more than a thousand years that it was used to treat TB, but this is not the type of direct moxa we have been investigating nor what is being used in the RCT.

Direct moxa took off on a slightly different path in Japan. Two factors mark it out as being quite different: firstly, the moxa used is more refined and so burns faster at a softer heat; and secondly the cones are quite tiny, often no more than the size of half a grain of rice.

Again, this technique was used to treat TB. We have good documentary evidence of its use as late as the 1940s when the TB drugs finally arrived. There is even some very interesting animal research in its use.

Since then this small cone technique has been further investigated in Japan right up to today, but not for TB – looking at basic immune response, particularly looking at possible applications in cancer treatment.

We’re quite comfortable in saying that its judicious regular use creates variable immune response which is probably dependent upon several factors which include cone sizes, points used and treatment regularity. We’ve published articles on this which have been quite well received. What has become more and more compelling as a result of the pilot studies we’ve completed in Africa, however, is that it really does seem to create powerful and positive effects on patients afflicted with TB, even if they are co-infected with HIV.

Make no bones about it, this is a bold hypothesis to promote, but it is one we are making now with the help of a bunch of pharmacologists at Makerere University in Uganda. We are putting it to the scientific acid test.

To our knowledge, nothing of this kind has ever been attempted before. Research in CAM and in acumoxa concerns itself almost exclusively with chronic disease and/or with pain perception. This research is a bit different - it is spotlighting the use of part of our medicine in the presence of a killer disease – in fact, in the presence of TWO killer diseases which also happen to be the two most lethal infectious diseases abroad today. It’s almost impossible to imagine a piece of acumoxa research that could be of more potential to mankind (in fact, possibly of ANY research..).

There’s a few other things which are important to understand: one is that the treatment is protocol-based and is simplicity itself; another is that there is (unlike acupuncture) no risk of cross-infection.It is also really easy to teach people to use the protocol treatment; a further one is that it is cheap and unpatentable. 


The next page deals with how you can help.